What one share of Adagio Medical Holdings holds
We are a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with our novel, proprietary, catheter-based Ultra-Low Temperature Ablation (“ULTA”) technology, formerly known as Ultra-Low Temperature Cryoablation (“ULTC”) technology.
Adagio Medical Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.28 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.83 |
| Cash and investments | $0.35 |
| Debt | $1.12 |
| Book value | −$0.02 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.39 | −$48.16 | $0.44 | −$34.20 | $0.00 | −$169.28 |
| 2025 | $0.00 | −$1.51 | $0.02 | −$1.17 | — | $0.56 |
Common questions about Adagio Medical Holdings
How much does one share of Adagio Medical Holdings earn?
Over the last 12 months, Adagio Medical Holdings lost $1.28 for each share.
Does Adagio Medical Holdings pay a dividend?
Adagio Medical Holdings didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Adagio Medical Holdings’s book value per share?
Adagio Medical Holdings’s book value is negative (−$0.02 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Adagio Medical Holdings have?
Each share of Adagio Medical Holdings has $0.35 of cash and investments and $1.12 of debt, as of June 30, 2026.
What is Adagio Medical Holdings’s free cash flow per share?
−$0.83 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.